ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia Between January 2013 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results